<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7476961\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="drug discovery against coronaviruses owing to their crucial role in" exact="viral" post="entry and host-cell invasion. Crystal structures of therapeutically important"/>
  <result pre="and treatment opportunities for COVID-19. Keywords SARS-CoV-2 Coronavirus RNA virus" exact="Respiratory" post="disease SARS-CoV-2 inhibitors 1 Introduction Coronavirus disease 2019 (COVID-19)"/>
  <result pre="treatment opportunities for COVID-19. Keywords SARS-CoV-2 Coronavirus RNA virus Respiratory" exact="disease" post="SARS-CoV-2 inhibitors 1 Introduction Coronavirus disease 2019 (COVID-19) is"/>
  <result pre="Coronavirus RNA virus Respiratory disease SARS-CoV-2 inhibitors 1 Introduction Coronavirus" exact="disease" post="2019 (COVID-19) is a pandemic faced by the global"/>
  <result pre="coronaviridae family, other members of which are known to cause" exact="respiratory" post="infections in humans [2]. The rapid torrent of COVID-19"/>
  <result pre="family, other members of which are known to cause respiratory" exact="infections" post="in humans [2]. The rapid torrent of COVID-19 infections"/>
  <result pre="respiratory infections in humans [2]. The rapid torrent of COVID-19" exact="infections" post="around the globe at an alarming rate is due"/>
  <result pre="higher than the SARS-CoV-1, with the main transmission route being" exact="respiratory" post="droplets and contact. Based on phylogenetic analysis, the natural"/>
  <result pre="to date, there has not been any confirmation regarding the" exact="intermediate" post="host [3], [4]. The virus was found to have"/>
  <result pre="from COVID-19. [5], [6]. Broadly pyrexia, cough, hemoptysis, diarrhea, dyspnoea," exact="muscle" post="soreness, lymphopenia, dysosmia, and dysgeusia are the symptoms associated"/>
  <result pre="dysgeusia are the symptoms associated with COVID-19, but certain symptoms" exact="atypical" post="from other coronavirus infections are to be acknowledged. They"/>
  <result pre="associated with COVID-19, but certain symptoms atypical from other coronavirus" exact="infections" post="are to be acknowledged. They include the presence of"/>
  <result pre="distress in some of the cases, and clinical manifestations of" exact="lower" post="respiratory tract infection, which are to be addressed [7],"/>
  <result pre="in some of the cases, and clinical manifestations of lower" exact="respiratory" post="tract infection, which are to be addressed [7], [8]."/>
  <result pre="[9]. SARS-CoV-2 is an enveloped, single-stranded positive-sense RNA virus. The" exact="viral" post="RNA genome contains 29,903 nucleotide bases and has ten"/>
  <result pre="resulting in conformational changes that lead to the fusion of" exact="viral" post="and cell membranes. Inside the endocytic vesicle, pH-dependent activation"/>
  <result pre="the spike proteins that result in the release of the" exact="viral" post="RNA genome into the cytoplasm (endocytic pathway). Alternatively, Transmembrane"/>
  <result pre="genome into the cytoplasm (endocytic pathway). Alternatively, Transmembrane Protease Serine" exact="type 2" post="(TMPRSS2) is also involved in priming of the spike"/>
  <result pre="spike proteins at the cell surface, enabling entry of the" exact="viral" post="genome (non-endocytic pathway). Once inside the cytoplasm, the ORF1ab"/>
  <result pre="pathway). Once inside the cytoplasm, the ORF1ab fragment of the" exact="viral" post="RNA genome is translated into the replicase polyprotein PP1ab,"/>
  <result pre="into the replicase polyprotein PP1ab, which is acted upon by" exact="viral" post="enzymes like PLpro and 3CLpro (Mpro) to produce nsps"/>
  <result pre="produce a negative-strand template for the synthesis of the new" exact="viral" post="RNA genome. The transcribed mRNAs are translated to produce"/>
  <result pre="to produce structural proteins S, M, E, and N. The" exact="viral" post="RNA genome along with the N protein interacts with"/>
  <result pre="protein, N: Nucleocapsid protein, M: Membrane protein, ERGIC: Endoplasmic reticulum-Golgi" exact="intermediate" post="compartment. 1.1 Approaches to anti-coronavirus drug discovery In general,"/>
  <result pre="drugs) that have been used or previously tested for other" exact="viral" post="infections by using standardized assays that measures the effects"/>
  <result pre="that have been used or previously tested for other viral" exact="infections" post="by using standardized assays that measures the effects of"/>
  <result pre="that measures the effects of these compounds on virus yields," exact="infection" post="rates, virus entry, and plaque formation. Some of the"/>
  <result pre="targeting the spike proteins, development of novel inhibitors targeting different" exact="viral" post="enzymes, development of inhibitors targeting host cellular proteases., development"/>
  <result pre="(aa 319-541) [21], [22]. The RBD consists of core and" exact="external" post="sub-domains responsible for forming trimer particle and for interaction"/>
  <result pre="fusion core bringing about the close association of cellular and" exact="viral" post="membranes for fusion [22]. Xia et al. designed novel"/>
  <result pre="and EK1 were also found to effectively inhibit 2019-nCoV pseudovirus" exact="infection" post="in 293Â T cells with IC50 values of 0.98Â"/>
  <result pre="and 2.38Â ÂµM, respectively (Fig. 4 ). Fig. 4 Peptide" exact="viral" post="entry inhibitors. Following the initial findings, Xia et al."/>
  <result pre="linker/spacer GSGSG-PGE4. EK1C4 also exhibited potent activity against SARS-CoV-2 pseudovirus" exact="infection" post="and live SARS-CoV-2 infection in vitro with IC50 values"/>
  <result pre="exhibited potent activity against SARS-CoV-2 pseudovirus infection and live SARS-CoV-2" exact="infection" post="in vitro with IC50 values of 15.8Â nM and"/>
  <result pre="the prophylactic and post-infection potential of EK1C4 on the HCoV-OC43" exact="infection" post="mouse model. The studies revealed that EK1C4 was effective"/>
  <result pre="effective prophylactically up to 12Â h before challenging with the" exact="infection" post="at a dose of 0.5Â mg/kg intranasally, suggesting good"/>
  <result pre="to SARS-CoV-2 RBD (KDÂ =Â 14.7Â nM). Fig. 5 Peptide" exact="viral" post="entry inhibitors. 2.2 Extracellular proteases Entry and invasion of"/>
  <result pre="Angiotensin II and Angiotensin 1-7 have opposing effects on the" exact="vascular" post="dynamics, the former being vasoconstrictive in nature and latter"/>
  <result pre="the suppressive axis of the classical renin-angiotensin system (RAS) [34]." exact="Chronic" post="administration of Angiotensin Receptor Blockers (ARBs) leads to the"/>
  <result pre="SARS patients. Studies have shown downregulation in ACE-2 levels following" exact="viral" post="attachment and fusion. This leads to the elevation of"/>
  <result pre="cellular protease encoded by the TMPRSS2 gene. TMPRSS2 is predominantly" exact="localized" post="in the cell membrane of the lungâ€™s epithelial cells"/>
  <result pre="is predominantly localized in the cell membrane of the lungâ€™s" exact="epithelial" post="cells and aids in priming the spike proteins, a"/>
  <result pre="spike proteins, a process that results in the fusion of" exact="viral" post="and cellular membranes. Previous results have shown that the"/>
  <result pre="also known to activate fusion proteins of viruses like Human" exact="immunodeficiency" post="virus (HIV), Ebola, highly pathogenic avian influenza A virus"/>
  <result pre="of viruses like Human immunodeficiency virus (HIV), Ebola, highly pathogenic" exact="avian influenza" post="A virus (HPAIV) as well as human coronaviruses like"/>
  <result pre="furin is essential for the multiplication of SARS-CoV-2 in airway" exact="epithelial" post="cells and hence provides a favorable target of further"/>
  <result pre="of the critical processes regarding endosomal proliferation and assembly of" exact="viral" post="proteins require the processing of these proteins through intracellular"/>
  <result pre="essential role in the life cycle of RNA viruses like" exact="hepatitis C" post="virus, Zika virus, and coronaviruses [57], [58]. In SARS-Cov-1"/>
  <result pre="nsp12, was investigated based on modeling with sofosbuvir bound to" exact="hepatitis C" post="virus (HCV) ns5b. The nsp12 of the SARS CoV-2"/>
  <result pre="HCV polymerase. Sofosbuvir has been approved for the treatment of" exact="chronic" post="HCV infection [66]. The catalytic site of SARS CoV-2"/>
  <result pre="Sofosbuvir has been approved for the treatment of chronic HCV" exact="infection" post="[66]. The catalytic site of SARS CoV-2 nsp13 shows"/>
  <result pre="amino acid long and is translated from the Orf1ab of" exact="viral" post="RNA genome[67]. Mpro is known to cleave the replicase"/>
  <result pre="to release 12 nsps (nsp4, nsp6-16) that are essential for" exact="viral" post="replication as well as viral assembly [10], [67]. Structurally,"/>
  <result pre="nsp6-16) that are essential for viral replication as well as" exact="viral" post="assembly [10], [67]. Structurally, Mpro is a dimer, and"/>
  <result pre="active against the SARS-CoV Mpro in picomolar concentration [69]. However," exact="short" post="half-life in plasma and unfavorable pharmacokinetic profile of compound"/>
  <result pre="inhibitory potential against SARS-CoV-2 in Vero E6 cells and human" exact="epithelial" post="pulmonary cell lines (A549). The solo treatment, as well"/>
  <result pre="potential against SARS-CoV-2 in Vero E6 cells and human epithelial" exact="pulmonary" post="cell lines (A549). The solo treatment, as well as"/>
  <result pre="releasing the nsp-1, nsp-2, and nsp-3, which are essential for" exact="viral" post="replication [10]. Apart from its proteolytic function, PLpro is"/>
  <result pre="role in countering the strength of host immune response to" exact="viral infection" post="by shutting down crucial pathways [78], [79], [80]. Currently,"/>
  <result pre="in countering the strength of host immune response to viral" exact="infection" post="by shutting down crucial pathways [78], [79], [80]. Currently,"/>
  <result pre="have major adverse effects like cardiac abnormalities, hepatic failure, and" exact="respiratory" post="depression, respectively [82], [83], [84]. Fig. 17 Structure of"/>
  <result pre="against other flavo viruses like Marburg virus, Pneumo viruses like" exact="respiratory" post="syncytial virus, and paramyxoviruses like mumps, measles, Nipah virus,"/>
  <result pre="potential of remdesivir in the rhesus macaque model of MERS-CoV" exact="infection" post="[88]. Remdesivir potently inhibited the replication of SARS-CoV and"/>
  <result pre="inhibited the replication of SARS-CoV and MERS-CoV in human airway" exact="epithelial" post="cell cultures with IC50 values of 0.069 and 0.074Â"/>
  <result pre="coronavirus SARS-CoV-2 in vitro. Remdesivir was effective in blocking the" exact="viral infection" post="in Vero E6 cells infected with nCoV-2019BetaCoV/Wuhan/WIV04/2019 (EC50Â =Â"/>
  <result pre="SARS-CoV-2 in vitro. Remdesivir was effective in blocking the viral" exact="infection" post="in Vero E6 cells infected with nCoV-2019BetaCoV/Wuhan/WIV04/2019 (EC50Â =Â"/>
  <result pre="Mechanism of action Remdesivir being a nucleoside analog inhibits the" exact="viral" post="genome replication process by targeting the RdRp enzyme. After"/>
  <result pre="lopinavir/ritonavir offered no benefits over the standard care in hospitalized" exact="adult" post="COVID-19 patients [102]. Considering the dynamic situation and differential"/>
  <result pre="favipiravir had better treatment outcomes on COVID-19 in terms of" exact="viral" post="clearance and disease progression [108]. A clear understanding of"/>
  <result pre="treatment outcomes on COVID-19 in terms of viral clearance and" exact="disease" post="progression [108]. A clear understanding of clinical pharmacokinetics and"/>
  <result pre="has been used for the treatment of RNA viruses like" exact="hepatitis" post="and respiratory syncytial virus. It interferes with the viral"/>
  <result pre="used for the treatment of RNA viruses like hepatitis and" exact="respiratory" post="syncytial virus. It interferes with the viral RNA synthesis"/>
  <result pre="like hepatitis and respiratory syncytial virus. It interferes with the" exact="viral" post="RNA synthesis and viral mRNA capping after undergoing metabolic"/>
  <result pre="syncytial virus. It interferes with the viral RNA synthesis and" exact="viral" post="mRNA capping after undergoing metabolic activation to its active"/>
  <result pre="of glycopeptide antibiotic is used for the treatment of gram-positive" exact="bacterial infections." post="The previous report suggested that teicoplanin and its derivatives"/>
  <result pre="that teicoplanin and its derivatives were capable of blocking the" exact="viral" post="entry of the Ebola virus, SARS-CoV, and MERS-CoV into"/>
  <result pre="as a dual inhibitor of the SARS-CoV-2 and its associated" exact="bacterial" post="co-infections. However, further evidence is required to support such"/>
  <result pre="broad-spectrum antibiotic that is used for the management of several" exact="bacterial infections" post="(Fig. 20 ). A recently conducted clinical trial highlighted"/>
  <result pre="antibiotic that is used for the management of several bacterial" exact="infections" post="(Fig. 20 ). A recently conducted clinical trial highlighted"/>
  <result pre="highlighted the importance of azithromycin for the management of SARS-CoV-2" exact="infection" post="[117]. A total of 36 patients were enrolled for"/>
  <result pre="of azithromycin for the management of SARS-CoV-2 infection [117]. A" exact="total" post="of 36 patients were enrolled for the study, out"/>
  <result pre="patients, six patients received azithromycin as a precautionary measure against" exact="bacterial" post="superinfection. At the end of day 6, 100% of"/>
  <result pre="COVID-19. Carrimycin has been patented for the treatment of mycobacterial" exact="infections" post="(European patent EP 3384915 A1). However, after a thorough"/>
  <result pre="prowess of chloroquine against the SARS-CoV-2. Chloroquine effectively blocked the" exact="viral infection" post="with a high selectivity index (EC50Â =Â 1.13Â ÂµM)"/>
  <result pre="of chloroquine against the SARS-CoV-2. Chloroquine effectively blocked the viral" exact="infection" post="with a high selectivity index (EC50Â =Â 1.13Â ÂµM)"/>
  <result pre="their pH thereby inactivating several proteolytic enzymes. Evidence suggests that" exact="viral" post="entry, replication, and infection requires an acidic environment in"/>
  <result pre="several proteolytic enzymes. Evidence suggests that viral entry, replication, and" exact="infection" post="requires an acidic environment in the endosome-lysosomes and the"/>
  <result pre="ACE-2 receptor and SARS-CoV-1 S protein is necessary for the" exact="viral" post="entry into the cell. Chloroquine impairs the Golgi mediated"/>
  <result pre="to SARS-CoV-1 S proteins. Hence weak interaction ensues, and the" exact="viral" post="entry is prevented [124]. 3.3.2 Nitazoxanide Nitazoxanide, a thiazolide"/>
  <result pre="agent used for the treatment of various protozoal and helminthic" exact="infections" post="[134]. Apart from its antiprotozoal potential, nitazoxanide has established"/>
  <result pre="of 5Â ÂµM resulted in an about 5000-fold reduction in" exact="viral" post="titers following 48Â h of ivermectin treatment. The safety"/>
  <result pre="=Â 22.50Â ÂµM) [62]. Scientists from Research Center for Asian" exact="Infectious" post="Diseases of the Institute of Medical Science, the University"/>
  <result pre="22.50Â ÂµM) [62]. Scientists from Research Center for Asian Infectious" exact="Diseases" post="of the Institute of Medical Science, the University of"/>
  <result pre="higher levels of IL-7, IL-2, IL-10, Granulocyte colony-stimulating factor (GCSF)," exact="Monocyte" post="chemoattractant protein-1 (MCP-1), Tumor necrosis factor- Î± (TNF-Î±) compared"/>
  <result pre="IL-2, IL-10, Granulocyte colony-stimulating factor (GCSF), Monocyte chemoattractant protein-1 (MCP-1)," exact="Tumor" post="necrosis factor- Î± (TNF-Î±) compared with non-ICU patients suggesting"/>
  <result pre="patients suggesting a possible cytokine storm that ultimately culminates in" exact="Acute" post="Respiratory Distress Syndrome (ARDS) [143]. Therefore, corticosteroids can be"/>
  <result pre="suggesting a possible cytokine storm that ultimately culminates in Acute" exact="Respiratory" post="Distress Syndrome (ARDS) [143]. Therefore, corticosteroids can be considered"/>
  <result pre="possible cytokine storm that ultimately culminates in Acute Respiratory Distress" exact="Syndrome" post="(ARDS) [143]. Therefore, corticosteroids can be considered as an"/>
  <result pre="to evaluate the efficacy of dexamethasone in patients with ARDS" exact="secondary" post="to SARS-CoV-2 infection (NCT04325061). Zhou et al. demonstrated that"/>
  <result pre="efficacy of dexamethasone in patients with ARDS secondary to SARS-CoV-2" exact="infection" post="(NCT04325061). Zhou et al. demonstrated that inflammatory and pro-inflammatory"/>
  <result pre="Granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-6 are highly expressed following" exact="viral infection" post="[146]. Therefore, blocking GM-CSF and IL-6 receptors can reduce"/>
  <result pre="colony-stimulating factor (GM-CSF) and IL-6 are highly expressed following viral" exact="infection" post="[146]. Therefore, blocking GM-CSF and IL-6 receptors can reduce"/>
  <result pre="fourth version of Diagnosis and Treatment Protocol for Novel Coronavirus" exact="Pneumonia" post="[152]. The TCM recommended in the current version (seventh"/>
  <result pre="trial version) of Diagnosis and Treatment Protocol for Novel Coronavirus" exact="Pneumonia" post="are highlighted in Table 2[153]. Table 2 Chinese patent"/>
  <result pre="recommended under the diagnosis and treatment protocol for novel Coronavirus" exact="Pneumonia" post="(Trial version seven) [153]. Disease stage Clinical manifestation Recommended"/>
  <result pre="treatment protocol for novel Coronavirus Pneumonia (Trial version seven) [153]." exact="Disease" post="stage Clinical manifestation Recommended Chinese patent medicine Medical observation"/>
  <result pre="manifestation Recommended Chinese patent medicine Medical observation Fatigue and Gastrointestinal" exact="discomfort" post="HuoxiangZhengqi capsules Fatigue and fever Jinhua Qinggan granules, LianhuaQingwen"/>
  <result pre="ShufengJiedu capsules (granules), FangfengTongsheng pills (granules) Clinical treatment (confirmed cases)" exact="Severe" post="cases Xiyanping injection, Xuebijing injection, Reduning injection, Tanreqing injection,"/>
  <result pre="fever. The symptoms of all three patients improved after the" exact="consumption" post="of SHL, and the patients finally recovered without any"/>
  <result pre="of 411.2Â Âµg/ml. Electron microscopic studies revealed that LH caused" exact="viral" post="deformities. Furthermore, LH was also shown to suppress the"/>
  <result pre="USA [62], [94] Lopinavir Antiviral 26.63 Mpro inhibitor Serious cardiotoxicity," exact="lactic acidosis," post="acute renal failure reported in preterm neonates Phase 2"/>
  <result pre="[94] Lopinavir Antiviral 26.63 Mpro inhibitor Serious cardiotoxicity, lactic acidosis," exact="acute" post="renal failure reported in preterm neonates Phase 2 clinical"/>
  <result pre="Lopinavir Antiviral 26.63 Mpro inhibitor Serious cardiotoxicity, lactic acidosis, acute" exact="renal failure" post="reported in preterm neonates Phase 2 clinical trial (NCT04330690)"/>
  <result pre="trials (NCT04336904) [62], [164] Ribavirin Antiviral 106.5 RdRp inhibitor Teratogenic," exact="hemolytic anemia" post="Phase 3 clinical trials (NCT04392427) [62], [165] Umifenovir Antiviral"/>
  <result pre="(NCT04336904) [62], [164] Ribavirin Antiviral 106.5 RdRp inhibitor Teratogenic, hemolytic" exact="anemia" post="Phase 3 clinical trials (NCT04392427) [62], [165] Umifenovir Antiviral"/>
  <result pre="(NCT04252885) [166] Oseltamivir Antiviral â€&quot; â€&quot; Steven-Johnson syndrome, anaphylactic reactions," exact="cardiac arrhythmia," post="seizures have been reported Phase 3 clinical trials (NCT04338698)"/>
  <result pre="Oseltamivir Antiviral â€&quot; â€&quot; Steven-Johnson syndrome, anaphylactic reactions, cardiac arrhythmia," exact="seizures" post="have been reported Phase 3 clinical trials (NCT04338698) [167]"/>
  <result pre="Antiviral â€&quot; Mpro inhibitor Liver injury, severe skin reactions like" exact="erythema multiforme" post="and Steven-Johnson syndrome Phase 3 clinical trial (NCT04252274) [168]"/>
  <result pre="Liver injury, severe skin reactions like erythema multiforme and Steven-Johnson" exact="syndrome" post="Phase 3 clinical trial (NCT04252274) [168] Teicoplanin Antibiotic 1.66"/>
  <result pre="â€&quot; [47] Azithromycin Antibiotic â€&quot; â€&quot; QT interval prolongation, severe" exact="hypersensitivity" post="reactions have been reported Phase 3 clinical trial (NCT04332107)"/>
  <result pre="Hyperkalemia, agranulocytosis, anaphylaxis Phase 2 clinical trial (NCT04418128) [62], [171]" exact="Infectious" post="diseases resulting from novel pathogens will continue to be"/>
  <result pre="world is still unprepared for such epidemics/pandemics despite former coronaviruses" exact="infections" post="SARS-CoV and MERS-CoV. Although vaccines are the only way"/>
  <result pre="coronavirusJ. Travel Med.27202010.1093/jtm/taaa021 4ParkS.E.Epidemiology, virology, and clinical features of severe" exact="acute" post="respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19)Clin. Exp. Pediatr.63202011912410.3345/cep.2020.0049332252141 5AdhikariS.P.MengS.WuY.-J.MaoY.-P.YeR.-X.WangQ.-Z.SunC.SylviaS.RozelleS.RaatH.ZhouH.Epidemiology,"/>
  <result pre="Travel Med.27202010.1093/jtm/taaa021 4ParkS.E.Epidemiology, virology, and clinical features of severe acute" exact="respiratory" post="syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19)Clin. Exp. Pediatr.63202011912410.3345/cep.2020.0049332252141 5AdhikariS.P.MengS.WuY.-J.MaoY.-P.YeR.-X.WangQ.-Z.SunC.SylviaS.RozelleS.RaatH.ZhouH.Epidemiology, causes,"/>
  <result pre="Med.27202010.1093/jtm/taaa021 4ParkS.E.Epidemiology, virology, and clinical features of severe acute respiratory" exact="syndrome" post="-coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19)Clin. Exp. Pediatr.63202011912410.3345/cep.2020.0049332252141 5AdhikariS.P.MengS.WuY.-J.MaoY.-P.YeR.-X.WangQ.-Z.SunC.SylviaS.RozelleS.RaatH.ZhouH.Epidemiology, causes, clinical"/>
  <result pre="causes, clinical manifestation and diagnosis, prevention and control of coronavirus" exact="disease" post="(COVID-19) during the early outbreak period: a scoping reviewInfect."/>
  <result pre="(accessed April 29, 2020). 7RothanH.A.ByrareddyS.N.The epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreakJ. Autoimmun.1024332020 8KeyhanS.O.FallahiH.R.CheshmiB.Dysosmia and dysgeusia due to the"/>
  <result pre="E.C. Holmes, Y.-Z. Zhang, A new coronavirus associated with human" exact="respiratory" post="disease in China Supplementary information, (n.d.). doi:10.1038/s41586-020-2008-3. 12ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.Y.Coronaviruses-drug discovery"/>
  <result pre="Holmes, Y.-Z. Zhang, A new coronavirus associated with human respiratory" exact="disease" post="in China Supplementary information, (n.d.). doi:10.1038/s41586-020-2008-3. 12ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.Y.Coronaviruses-drug discovery and"/>
  <result pre="and ribavirinSci. Rep.3201310.1038/srep01686 15ChanJ.F.W.ChanK.H.KaoR.Y.T.ToK.K.W.ZhengB.J.LiC.P.Y.LiP.T.W.DaiJ.MokF.K.Y.ChenH.HaydenF.G.YuenK.Y.Broad-spectrum antivirals for the emerging Middle East" exact="respiratory" post="syndrome coronavirusJ. Infect.67201360661610.1016/j.jinf.2013.09.02924096239 16ElshabrawyH.A.FanJ.HaddadC.S.RatiaK.BroderC.C.CaffreyM.PrabhakarB.S.Identification of a broad-spectrum antiviral small"/>
  <result pre="ribavirinSci. Rep.3201310.1038/srep01686 15ChanJ.F.W.ChanK.H.KaoR.Y.T.ToK.K.W.ZhengB.J.LiC.P.Y.LiP.T.W.DaiJ.MokF.K.Y.ChenH.HaydenF.G.YuenK.Y.Broad-spectrum antivirals for the emerging Middle East respiratory" exact="syndrome" post="coronavirusJ. Infect.67201360661610.1016/j.jinf.2013.09.02924096239 16ElshabrawyH.A.FanJ.HaddadC.S.RatiaK.BroderC.C.CaffreyM.PrabhakarB.S.Identification of a broad-spectrum antiviral small molecule"/>
  <result pre="Infect.67201360661610.1016/j.jinf.2013.09.02924096239 16ElshabrawyH.A.FanJ.HaddadC.S.RatiaK.BroderC.C.CaffreyM.PrabhakarB.S.Identification of a broad-spectrum antiviral small molecule against severe" exact="acute" post="respiratory syndrome coronavirus and ebola, hendra, and nipah viruses"/>
  <result pre="16ElshabrawyH.A.FanJ.HaddadC.S.RatiaK.BroderC.C.CaffreyM.PrabhakarB.S.Identification of a broad-spectrum antiviral small molecule against severe acute" exact="respiratory" post="syndrome coronavirus and ebola, hendra, and nipah viruses by"/>
  <result pre="of a broad-spectrum antiviral small molecule against severe acute respiratory" exact="syndrome" post="coronavirus and ebola, hendra, and nipah viruses by using"/>
  <result pre="17DyallJ.ColemanC.M.HartB.J.VenkataramanT.HolbrookM.R.KindrachukJ.JohnsonR.F.OlingerG.G.JahrlingP.B.LaidlawM.JohansenL.M.Lear-RooneyC.M.GlassP.J.HensleyL.E.FriemanM.B.Repurposing of clinically developed drugs for treatment of middle east" exact="respiratory" post="syndrome coronavirus infectionAm Soc Microbiol.201410.1128/AAC.03036-14 18GordonD.E.JangG.M.BouhaddouM.XuJ.ObernierK.WhiteK.M.Oâ€™MearaM.J.RezeljV.V.GuoJ.Z.SwaneyD.L.TumminoT.A.HuettenhainR.KaakeR.M.RichardsA.L.TutuncuogluB.FoussardH.BatraJ.HaasK.ModakM.KimM.HaasP.PolaccoB.J.BrabergH.FabiusJ.M.EckhardtM.SoucherayM.BennettM.J.CakirM.McGregorM.J.LiQ.MeyerB.RoeschF.ValletT.Mac KainA.MiorinL.MorenoE.NaingZ.Z.C.ZhouY.PengS.ShiY.ZhangZ.ShenW.KirbyI.T.MelnykJ.E.ChorbaJ.S.LouK.DaiS.A.Barrio-HernandezI.MemonD.Hernandez-ArmentaC.LyuJ.MathyC.J.P.PericaT.PillaK.B.GanesanS.J.SaltzbergD.J.RakeshR.LiuX.RosenthalS.B.CalvielloL.VenkataramananS.Liboy-LugoJ.LinY.HuangX.P.LiuY.F.WankowiczS.A.BohnM.SafariM.UgurF.S.KohC.SavarN.S.TranQ.D.ShengjulerD.FletcherS.J.Oâ€™NealM.C.CaiY.ChangJ.C.J.BroadhurstD.J.KlippstenS.SharpP.P.WenzellN.A.KuzuogluD.WangH.Y.TrenkerR.YoungJ.M.CaveroD.A.HiattJ.RothT.L.RathoreU.SubramanianA.NoackJ.HubertM.StroudR.M.FrankelA.D.RosenbergO.S.VerbaK.A.AgardD.A.OttM.EmermanM.JuraN.von ZastrowM.VerdinE.AshworthA.SchwartzO.dâ€™EnfertC.MukherjeeS.JacobsonM.MalikH.S.FujimoriD.G.IdekerT.CraikC.S.FloorS.N.FraserJ.S.GrossJ.D.SaliA.RothB.L.RuggeroD.TauntonJ.KortemmeT.BeltraoP.VignuzziM.GarcÃ­a-SastreA.ShokatK.M.ShoichetB.K.KroganN.J.A SARS-CoV-2"/>
  <result pre="of clinically developed drugs for treatment of middle east respiratory" exact="syndrome" post="coronavirus infectionAm Soc Microbiol.201410.1128/AAC.03036-14 18GordonD.E.JangG.M.BouhaddouM.XuJ.ObernierK.WhiteK.M.Oâ€™MearaM.J.RezeljV.V.GuoJ.Z.SwaneyD.L.TumminoT.A.HuettenhainR.KaakeR.M.RichardsA.L.TutuncuogluB.FoussardH.BatraJ.HaasK.ModakM.KimM.HaasP.PolaccoB.J.BrabergH.FabiusJ.M.EckhardtM.SoucherayM.BennettM.J.CakirM.McGregorM.J.LiQ.MeyerB.RoeschF.ValletT.Mac KainA.MiorinL.MorenoE.NaingZ.Z.C.ZhouY.PengS.ShiY.ZhangZ.ShenW.KirbyI.T.MelnykJ.E.ChorbaJ.S.LouK.DaiS.A.Barrio-HernandezI.MemonD.Hernandez-ArmentaC.LyuJ.MathyC.J.P.PericaT.PillaK.B.GanesanS.J.SaltzbergD.J.RakeshR.LiuX.RosenthalS.B.CalvielloL.VenkataramananS.Liboy-LugoJ.LinY.HuangX.P.LiuY.F.WankowiczS.A.BohnM.SafariM.UgurF.S.KohC.SavarN.S.TranQ.D.ShengjulerD.FletcherS.J.Oâ€™NealM.C.CaiY.ChangJ.C.J.BroadhurstD.J.KlippstenS.SharpP.P.WenzellN.A.KuzuogluD.WangH.Y.TrenkerR.YoungJ.M.CaveroD.A.HiattJ.RothT.L.RathoreU.SubramanianA.NoackJ.HubertM.StroudR.M.FrankelA.D.RosenbergO.S.VerbaK.A.AgardD.A.OttM.EmermanM.JuraN.von ZastrowM.VerdinE.AshworthA.SchwartzO.dâ€™EnfertC.MukherjeeS.JacobsonM.MalikH.S.FujimoriD.G.IdekerT.CraikC.S.FloorS.N.FraserJ.S.GrossJ.D.SaliA.RothB.L.RuggeroD.TauntonJ.KortemmeT.BeltraoP.VignuzziM.GarcÃ­a-SastreA.ShokatK.M.ShoichetB.K.KroganN.J.A SARS-CoV-2 protein"/>
  <result pre="of coronavirus spike proteins and host ACE2 receptors predict potential" exact="intermediate" post="hosts of SARS-CoV-2J. Med. Virol.202010.1002/jmv.25726 22XiaS.ZhuY.LiuM.LanQ.XuW.WuY.YingT.LiuS.ShiZ.JiangS.LuL.Fusion mechanism of 2019-nCoV"/>
  <result pre="receptor CD26Nature500201322723110.1038/nature1232823831647 24F. Li, W. Li, M. Farzan, S.C. Harrison," exact="Structural" post="biology: Structure of SARS coronavirus spike receptor-binding domain complexed"/>
  <result pre="and identification of fusion inhibitorsLancet363200493894710.1016/S0140-6736(04)15788-715043961 26LuL.LiuQ.ZhuY.ChanK.H.QinL.LiY.WangQ.ChanJ.F.W.DuL.YuF.MaC.YeS.YuenK.Y.ZhangR.JiangS.Structure-based discovery of Middle East" exact="respiratory" post="syndrome coronavirus fusion inhibitorNat. Commun.5201410.1038/ncomms4067 27XiaS.YanL.XuW.AgrawalA.S.AlgaissiA.TsengC.T.K.WangQ.DuL.TanW.WilsonI.A.JiangS.YangB.LuL.A pan-coronavirus fusion inhibitor"/>
  <result pre="identification of fusion inhibitorsLancet363200493894710.1016/S0140-6736(04)15788-715043961 26LuL.LiuQ.ZhuY.ChanK.H.QinL.LiY.WangQ.ChanJ.F.W.DuL.YuF.MaC.YeS.YuenK.Y.ZhangR.JiangS.Structure-based discovery of Middle East respiratory" exact="syndrome" post="coronavirus fusion inhibitorNat. Commun.5201410.1038/ncomms4067 27XiaS.YanL.XuW.AgrawalA.S.AlgaissiA.TsengC.T.K.WangQ.DuL.TanW.WilsonI.A.JiangS.YangB.LuL.A pan-coronavirus fusion inhibitor targeting"/>
  <result pre="of human coronavirus spikeSci. Adv.5201910.1126/sciadv.aav4580 28XiaS.LiuM.WangC.XuW.LanQ.FengS.QiF.BaoL.DuL.LiuS.QinC.SunF.ShiZ.ZhuY.JiangS.LuL.Inhibition of SARS-CoV-2 (previously 2019-nCoV)" exact="infection" post="by a highly potent pan-coronavirus fusion inhibitor targeting its"/>
  <result pre="receptor for SARS coronavirusCell. Mol. Life Sci.6120042738274310.1007/s00018-004-4242-515549175 32ZhouP.Lou YangX.WangX.G.HuB.ZhangL.ZhangW.SiH.R.ZhuY.LiB.HuangC.L.ChenH.D.ChenJ.LuoY.GuoH.Di JiangR.LiuM.Q.ChenY.ShenX.R.WangX.ZhengX.S.ZhaoK.ChenQ.J.DengF.LiuL.L.YanB.ZhanF.X.WangY.Y.XiaoG.F.ShiZ.L.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="a clinically proven protease inhibitorCell202011010.1016/j.cell.2020.02.052 34Paz OcaranzaM.RiquelmeJ.A.GarcÃ­aL.JalilJ.E.ChiongM.SantosR.A.S.LavanderoS.Counter-regulatory reninâ€&quot;angiotensin system in" exact="cardiovascular" post="diseaseNat. Rev. Cardiol.17202011612910.1038/s41569-019-0244-831427727 35KlimasJ.OlvedyM.Ochodnicka-MackovicovaK.KruzliakP.CacanyiovaS.KristekF.KrenekP.OchodnickyP.Perinatally administered losartan augments renal ACE2"/>
  <result pre="immune cross-reactivity with SARS-CoVNat. Commun.112020162010.1038/s41467-020-15562-932221306 40MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient activation of the severe" exact="acute" post="respiratory syndrome coronavirus spike protein by the transmembrane protease"/>
  <result pre="cross-reactivity with SARS-CoVNat. Commun.112020162010.1038/s41467-020-15562-932221306 40MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient activation of the severe acute" exact="respiratory" post="syndrome coronavirus spike protein by the transmembrane protease TMPRSS2J."/>
  <result pre="with SARS-CoVNat. Commun.112020162010.1038/s41467-020-15562-932221306 40MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient activation of the severe acute respiratory" exact="syndrome" post="coronavirus spike protein by the transmembrane protease TMPRSS2J. Virol.842010126581266410.1128/jvi.01542-1020926566"/>
  <result pre="transmembrane protease TMPRSS2J. Virol.842010126581266410.1128/jvi.01542-1020926566 41GlowackaI.BertramS.MullerM.A.AllenP.SoilleuxE.PfefferleS.SteffenI.TsegayeT.S.HeY.GnirssK.NiemeyerD.SchneiderH.DrostenC.PohlmannS.Evidence that TMPRSS2 activates the severe" exact="acute" post="respiratory syndrome coronavirus spike protein for membrane fusion and"/>
  <result pre="protease TMPRSS2J. Virol.842010126581266410.1128/jvi.01542-1020926566 41GlowackaI.BertramS.MullerM.A.AllenP.SoilleuxE.PfefferleS.SteffenI.TsegayeT.S.HeY.GnirssK.NiemeyerD.SchneiderH.DrostenC.PohlmannS.Evidence that TMPRSS2 activates the severe acute" exact="respiratory" post="syndrome coronavirus spike protein for membrane fusion and reduces"/>
  <result pre="TMPRSS2J. Virol.842010126581266410.1128/jvi.01542-1020926566 41GlowackaI.BertramS.MullerM.A.AllenP.SoilleuxE.PfefferleS.SteffenI.TsegayeT.S.HeY.GnirssK.NiemeyerD.SchneiderH.DrostenC.PohlmannS.Evidence that TMPRSS2 activates the severe acute respiratory" exact="syndrome" post="coronavirus spike protein for membrane fusion and reduces viral"/>
  <result pre="respiratory syndrome coronavirus spike protein for membrane fusion and reduces" exact="viral" post="control by the humoral immune responseJ. Virol.8520114122413410.1128/jvi.02232-1021325420 42S. Rensi,"/>
  <result pre="Cells, ChemRxiv. (n.d.). doi:10.26434/chemrxiv.12009582. 43SimmonsG.GosaliaD.N.RennekampA.J.ReevesJ.D.DiamondS.L.BatesP.Inhibitors of cathepsin L prevent severe" exact="acute" post="respiratory syndrome coronavirus entryProc. Natl. Acad. Sci. USA1022005118761188110.1073/pnas.050557710216081529 44HuangI.C.BoschB.J.LiF.LiW.KyoungH.L.GhiranS.VasilievaN.DermodyT.S.HarrisonS.C.DormitzerP.R.FarzanM.RottierP.J.M.ChoeH.SARS"/>
  <result pre="ChemRxiv. (n.d.). doi:10.26434/chemrxiv.12009582. 43SimmonsG.GosaliaD.N.RennekampA.J.ReevesJ.D.DiamondS.L.BatesP.Inhibitors of cathepsin L prevent severe acute" exact="respiratory" post="syndrome coronavirus entryProc. Natl. Acad. Sci. USA1022005118761188110.1073/pnas.050557710216081529 44HuangI.C.BoschB.J.LiF.LiW.KyoungH.L.GhiranS.VasilievaN.DermodyT.S.HarrisonS.C.DormitzerP.R.FarzanM.RottierP.J.M.ChoeH.SARS coronavirus,"/>
  <result pre="(n.d.). doi:10.26434/chemrxiv.12009582. 43SimmonsG.GosaliaD.N.RennekampA.J.ReevesJ.D.DiamondS.L.BatesP.Inhibitors of cathepsin L prevent severe acute respiratory" exact="syndrome" post="coronavirus entryProc. Natl. Acad. Sci. USA1022005118761188110.1073/pnas.050557710216081529 44HuangI.C.BoschB.J.LiF.LiW.KyoungH.L.GhiranS.VasilievaN.DermodyT.S.HarrisonS.C.DormitzerP.R.FarzanM.RottierP.J.M.ChoeH.SARS coronavirus, but"/>
  <result pre="endosome/lysosome and block the entry of ebola virus, middle east" exact="respiratory" post="syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus"/>
  <result pre="and block the entry of ebola virus, middle east respiratory" exact="syndrome" post="coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)J."/>
  <result pre="ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV)J. Biol. Chem.29120169218923210.1074/jbc.M116.71610026953343 47J. Zhang, X."/>
  <result pre="virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV)J. Biol. Chem.29120169218923210.1074/jbc.M116.71610026953343 47J. Zhang, X. Ma,"/>
  <result pre="middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV)J. Biol. Chem.29120169218923210.1074/jbc.M116.71610026953343 47J. Zhang, X. Ma, F."/>
  <result pre="Acta - Rev. Biomembr.1469200012113210.1016/S0304-4157(00)00014-9 51MilleJ.K.WhittakerG.R.Host cell entry of Middle East" exact="respiratory" post="syndrome coronavirus after two-step, furin-mediated activation of the spike"/>
  <result pre="- Rev. Biomembr.1469200012113210.1016/S0304-4157(00)00014-9 51MilleJ.K.WhittakerG.R.Host cell entry of Middle East respiratory" exact="syndrome" post="coronavirus after two-step, furin-mediated activation of the spike proteinProc."/>
  <result pre="Natl. Acad. Sci. USA1112014152141521910.1073/pnas.140708711125288733 52Le CoupanecA.DesforgesM.Meessen-PinardM.DubÃ©M.DayR.SeidahN.G.TalbotP.J.Cleavage of a neuroinvasive human" exact="respiratory" post="virus spike glycoprotein by proprotein convertases modulates neurovirulence and"/>
  <result pre="for proteolytic activation and spread of SARS-CoV-2 in human airway" exact="epithelial" post="cells and provide promising drug targets, BioRxiv. (2020) 2020.04.15.042085."/>
  <result pre="and provide promising drug targets, BioRxiv. (2020) 2020.04.15.042085. doi:10.1101/2020.04.15.042085. 57ElfikyA.A.Zika" exact="viral" post="polymerase inhibition using anti-HCV drugs both in market and"/>
  <result pre="compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East" exact="respiratory" post="syndrome coronavirusjbc.AC120.013056J. Biol. Chem.202010.1074/jbc.ac120.013056 59SubissiL.PosthumaC.C.ColletA.Zevenhoven-DobbeJ.C.GorbalenyaA.E.DecrolyE.SnijderE.J.CanardB.ImbertI.One severe acute respiratory syndrome"/>
  <result pre="remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory" exact="syndrome" post="coronavirusjbc.AC120.013056J. Biol. Chem.202010.1074/jbc.ac120.013056 59SubissiL.PosthumaC.C.ColletA.Zevenhoven-DobbeJ.C.GorbalenyaA.E.DecrolyE.SnijderE.J.CanardB.ImbertI.One severe acute respiratory syndrome coronavirus"/>
  <result pre="from Middle East respiratory syndrome coronavirusjbc.AC120.013056J. Biol. Chem.202010.1074/jbc.ac120.013056 59SubissiL.PosthumaC.C.ColletA.Zevenhoven-DobbeJ.C.GorbalenyaA.E.DecrolyE.SnijderE.J.CanardB.ImbertI.One severe" exact="acute" post="respiratory syndrome coronavirus protein complex integrates processive RNA polymerase"/>
  <result pre="Middle East respiratory syndrome coronavirusjbc.AC120.013056J. Biol. Chem.202010.1074/jbc.ac120.013056 59SubissiL.PosthumaC.C.ColletA.Zevenhoven-DobbeJ.C.GorbalenyaA.E.DecrolyE.SnijderE.J.CanardB.ImbertI.One severe acute" exact="respiratory" post="syndrome coronavirus protein complex integrates processive RNA polymerase and"/>
  <result pre="East respiratory syndrome coronavirusjbc.AC120.013056J. Biol. Chem.202010.1074/jbc.ac120.013056 59SubissiL.PosthumaC.C.ColletA.Zevenhoven-DobbeJ.C.GorbalenyaA.E.DecrolyE.SnijderE.J.CanardB.ImbertI.One severe acute respiratory" exact="syndrome" post="coronavirus protein complex integrates processive RNA polymerase and exonuclease"/>
  <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019-nCoVChemBioChem21202073073810.1002/cbic.20200004732022370 61ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.Y.Coronaviruses-drug discovery and therapeutic"/>
  <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019-nCoVChemBioChem21202073073810.1002/cbic.20200004732022370 61ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.Y.Coronaviruses-drug discovery and therapeutic optionsNat."/>
  <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019-nCoVChemBioChem21202073073810.1002/cbic.20200004732022370 61ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.Y.Coronaviruses-drug discovery and therapeutic optionsNat. Rev."/>
  <result pre="RNA-dependent RNA polymerase from COVID-19 virusScience202010.1126/science.abb7498 66HeoY.A.DeeksE.D.Sofosbuvir/velpatasvir/voxilaprevir: a review in" exact="chronic hepatitis" post="CDrugs78201857758710.1007/s40265-018-0895-529546556 67WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.HuY.TaoZ.W.TianJ.H.PeiY.Y.YuanM.L.ZhangY.L.DaiF.H.LiuY.WangQ.M.ZhengJ.J.XuL.HolmesE.C.ZhangY.Z.A new coronavirus associated with human respiratory disease"/>
  <result pre="RNA polymerase from COVID-19 virusScience202010.1126/science.abb7498 66HeoY.A.DeeksE.D.Sofosbuvir/velpatasvir/voxilaprevir: a review in chronic" exact="hepatitis" post="CDrugs78201857758710.1007/s40265-018-0895-529546556 67WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.HuY.TaoZ.W.TianJ.H.PeiY.Y.YuanM.L.ZhangY.L.DaiF.H.LiuY.WangQ.M.ZhengJ.J.XuL.HolmesE.C.ZhangY.Z.A new coronavirus associated with human respiratory disease"/>
  <result pre="in chronic hepatitis CDrugs78201857758710.1007/s40265-018-0895-529546556 67WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.HuY.TaoZ.W.TianJ.H.PeiY.Y.YuanM.L.ZhangY.L.DaiF.H.LiuY.WangQ.M.ZhengJ.J.XuL.HolmesE.C.ZhangY.Z.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature579202026526910.1038/s41586-020-2008-332015508 68L. Zhang, D. Lin, X. Sun,"/>
  <result pre="chronic hepatitis CDrugs78201857758710.1007/s40265-018-0895-529546556 67WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.HuY.TaoZ.W.TianJ.H.PeiY.Y.YuanM.L.ZhangY.L.DaiF.H.LiuY.WangQ.M.ZhengJ.J.XuL.HolmesE.C.ZhangY.Z.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature579202026526910.1038/s41586-020-2008-332015508 68L. Zhang, D. Lin, X. Sun, U."/>
  <result pre="glutathione peroxidase mimic, for the prevention and treatment of noise-induced" exact="hearing loss," post="in: Semin. Hear., Â© Thieme Medical Publishers, 2009: pp."/>
  <result pre="production, BioRxiv. (2020) 2020.04.04.020925. doi:10.1101/2020.04.04.020925. 77BarrettoN.JuknelieneD.RatiaK.ChenZ.MesecarA.D.BakerS.C.The papain-like protease of severe" exact="acute" post="respiratory syndrome coronavirus has deubiquitinating activityJ. Virol.792005151891519810.1128/jvi.79.24.15189-15198.200516306590 78YuanL.ChenZ.SongS.WangS.TianC.XingG.ChenX.XiaoZ.X.HeF.ZhangL.P53 degradation"/>
  <result pre="BioRxiv. (2020) 2020.04.04.020925. doi:10.1101/2020.04.04.020925. 77BarrettoN.JuknelieneD.RatiaK.ChenZ.MesecarA.D.BakerS.C.The papain-like protease of severe acute" exact="respiratory" post="syndrome coronavirus has deubiquitinating activityJ. Virol.792005151891519810.1128/jvi.79.24.15189-15198.200516306590 78YuanL.ChenZ.SongS.WangS.TianC.XingG.ChenX.XiaoZ.X.HeF.ZhangL.P53 degradation by"/>
  <result pre="(2020) 2020.04.04.020925. doi:10.1101/2020.04.04.020925. 77BarrettoN.JuknelieneD.RatiaK.ChenZ.MesecarA.D.BakerS.C.The papain-like protease of severe acute respiratory" exact="syndrome" post="coronavirus has deubiquitinating activityJ. Virol.792005151891519810.1128/jvi.79.24.15189-15198.200516306590 78YuanL.ChenZ.SongS.WangS.TianC.XingG.ChenX.XiaoZ.X.HeF.ZhangL.P53 degradation by a"/>
  <result pre="activityJ. Virol.792005151891519810.1128/jvi.79.24.15189-15198.200516306590 78YuanL.ChenZ.SongS.WangS.TianC.XingG.ChenX.XiaoZ.X.HeF.ZhangL.P53 degradation by a coronavirus papain-like protease suppresses" exact="type I" post="interferon signalingJ. Biol. Chem.29020153172318210.1074/jbc.M114.61989025505178 79ChenX.YangX.ZhengY.YangY.XingY.ChenZ.SARS coronavirus papain-like protease inhibits"/>
  <result pre="interferon signalingJ. Biol. Chem.29020153172318210.1074/jbc.M114.61989025505178 79ChenX.YangX.ZhengY.YangY.XingY.ChenZ.SARS coronavirus papain-like protease inhibits the" exact="type I" post="interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complexProtein"/>
  <result pre="a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe" exact="acute" post="respiratory syndrome coronavirus 2 with high potencyJ. Biol. Chem.202010.1074/jbc.RA120.013679"/>
  <result pre="direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute" exact="respiratory" post="syndrome coronavirus 2 with high potencyJ. Biol. Chem.202010.1074/jbc.RA120.013679 87LoM.K.JordanR.ArveyA.SudhamsuJ.Shrivastava-RanjanP.HotardA.L.FlintM.McMullanL.K.SiegelD.ClarkeM.O.MackmanR.L.HuiH.C.PerronM.RayA.S.CihlarT.NicholS.T.SpiropoulouC.F.GS-5734"/>
  <result pre="antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory" exact="syndrome" post="coronavirus 2 with high potencyJ. Biol. Chem.202010.1074/jbc.RA120.013679 87LoM.K.JordanR.ArveyA.SudhamsuJ.Shrivastava-RanjanP.HotardA.L.FlintM.McMullanL.K.SiegelD.ClarkeM.O.MackmanR.L.HuiH.C.PerronM.RayA.S.CihlarT.NicholS.T.SpiropoulouC.F.GS-5734 and"/>
  <result pre="phase 3 trial of investigational antiviral Remdesivir in patients with" exact="Severe" post="COVID-19, Gilead Sci. Inc. (2020) 1. https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/gilead-announces-results-from-phase-3-trial-of-remdesivir-in-patients-with-moderate-covid-19 (accessed June"/>
  <result pre="compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East" exact="respiratory" post="syndrome coronavirus., J. Biol. Chem. (2020). doi:10.1074/jbc.AC120.013056. 96CvetkovicR.S.GoaK.L.Lopinavir/ritonavir: A"/>
  <result pre="remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory" exact="syndrome" post="coronavirus., J. Biol. Chem. (2020). doi:10.1074/jbc.AC120.013056. 96CvetkovicR.S.GoaK.L.Lopinavir/ritonavir: A review"/>
  <result pre="FDA-approved compound library identifies four small-molecule inhibitors of Middle East" exact="respiratory" post="syndrome coronavirus replication in cell cultureAntimicrob. Agents Chemother.5820144875488410.1128/AAC.03011-1424841269 99ChanJ.F.-W.YaoY.YeungM.-L.DengW.BaoL.JiaL.LiF.XiaoC.GaoH.YuP.CaiJ.-P.ChuH.ZhouJ.ChenH.QinC.YuenK.-Y.Treatment"/>
  <result pre="compound library identifies four small-molecule inhibitors of Middle East respiratory" exact="syndrome" post="coronavirus replication in cell cultureAntimicrob. Agents Chemother.5820144875488410.1128/AAC.03011-1424841269 99ChanJ.F.-W.YaoY.YeungM.-L.DengW.BaoL.JiaL.LiF.XiaoC.GaoH.YuP.CaiJ.-P.ChuH.ZhouJ.ChenH.QinC.YuenK.-Y.Treatment with"/>
  <result pre="Chemother.5820144875488410.1128/AAC.03011-1424841269 99ChanJ.F.-W.YaoY.YeungM.-L.DengW.BaoL.JiaL.LiF.XiaoC.GaoH.YuP.CaiJ.-P.ChuH.ZhouJ.ChenH.QinC.YuenK.-Y.Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmosetJ. Infect."/>
  <result pre="antiviral agent T-705 (favipiravir)Mol. Pharmacol.84201361562910.1124/mol.113.08724723907213 104OestereichL.LÃ¼dtkeA.WurrS.RiegerT.MuÃ±oz-FontelaC.GÃ¼ntherS.Successful treatment of advanced Ebola" exact="virus infection" post="with T-705 (favipiravir) in a small animal modelAntiviral Res.1052014172110.1016/j.antiviral.2014.02.01424583123"/>
  <result pre="agent T-705 (favipiravir)Mol. Pharmacol.84201361562910.1124/mol.113.08724723907213 104OestereichL.LÃ¼dtkeA.WurrS.RiegerT.MuÃ±oz-FontelaC.GÃ¼ntherS.Successful treatment of advanced Ebola virus" exact="infection" post="with T-705 (favipiravir) in a small animal modelAntiviral Res.1052014172110.1016/j.antiviral.2014.02.01424583123"/>
  <result pre="X. Anglaret, D. Malvy, Experimental Treatment with Favipiravir for Ebola" exact="Virus Disease" post="(the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial"/>
  <result pre="Anglaret, D. Malvy, Experimental Treatment with Favipiravir for Ebola Virus" exact="Disease" post="(the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial"/>
  <result pre="macaquesNat. Med.1920131313131710.1038/nm.336224013700 112OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and interferon alfa-2a for severe Middle East" exact="respiratory" post="syndrome coronavirus infection: A retrospective cohort studyLancet Infect. Dis.1420141090109510.1016/S1473-3099(14)70920-X25278221"/>
  <result pre="Med.1920131313131710.1038/nm.336224013700 112OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and interferon alfa-2a for severe Middle East respiratory" exact="syndrome" post="coronavirus infection: A retrospective cohort studyLancet Infect. Dis.1420141090109510.1016/S1473-3099(14)70920-X25278221 113ArabiY.M.ShalhoubS.MandourahY.Al-HameedF.Al-OmariA.Al"/>
  <result pre="and interferon therapy for critically Ill patients with middle east" exact="respiratory" post="syndrome: a multicenter observational studyClin. Infect. Dis.201910.1093/cid/ciz544 114BlaisingJ.PolyakS.J.PÃ©cheurE.I.Arbidol as"/>
  <result pre="Infect. Dis.1201631732610.1021/acsinfecdis.5b00030 120DelvecchioR.HigaL.M.PezzutoP.ValadÃ£oA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.M.AliotaM.T.CaineE.A.OsorioJ.E.BellioM.Oâ€™ConnorD.H.RehenS.De AguiarR.S.SavarinoA.CampanatiL.TanuriA.Chloroquine, an endocytosis blocking agent, inhibits zika" exact="virus infection" post="in different cell modelsViruses8201610.3390/v8120322 121FreibergA.N.WorthyM.N.LeeB.HolbrookM.R.Combined chloroquine and ribavirin treatment"/>
  <result pre="Dis.1201631732610.1021/acsinfecdis.5b00030 120DelvecchioR.HigaL.M.PezzutoP.ValadÃ£oA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.M.AliotaM.T.CaineE.A.OsorioJ.E.BellioM.Oâ€™ConnorD.H.RehenS.De AguiarR.S.SavarinoA.CampanatiL.TanuriA.Chloroquine, an endocytosis blocking agent, inhibits zika virus" exact="infection" post="in different cell modelsViruses8201610.3390/v8120322 121FreibergA.N.WorthyM.N.LeeB.HolbrookM.R.Combined chloroquine and ribavirin treatment"/>
  <result pre="virus infectionJ. Gen. Virol.91201076577210.1099/vir.0.017269-019889926 122E.A. Kouroumalis, J. Koskinas, Treatment of" exact="chronic" post="active hepatitis B (CAH B) with chloroquine: a preliminary"/>
  <result pre="Gen. Virol.91201076577210.1099/vir.0.017269-019889926 122E.A. Kouroumalis, J. Koskinas, Treatment of chronic active" exact="hepatitis" post="B (CAH B) with chloroquine: a preliminary report, Ann."/>
  <result pre="149â€&quot;152. http://www.ncbi.nlm.nih.gov/pubmed/3752892 (accessed March 31, 2020). 123KoyamaA.H.UchidaT.Inhibition of multiplication of" exact="herpes" post="simplex virus type 1 by ammonium chloride and chloroquineVirology138198433233510.1016/0042-6822(84)90356-86093369"/>
  <result pre="March 31, 2020). 123KoyamaA.H.UchidaT.Inhibition of multiplication of herpes simplex virus" exact="type 1" post="by ammonium chloride and chloroquineVirology138198433233510.1016/0042-6822(84)90356-86093369 124VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent"/>
  <result pre="and chloroquineVirology138198433233510.1016/0042-6822(84)90356-86093369 124VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.2200510.1186/1743-422X-2-69 125GaoJ.TianZ.YangX.Breakthrough: Chloroquine phosphate has shown apparent"/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci. Trends142020727310.5582/bst.2020.0104732074550 126LiuJ.CaoR.XuM.WangX.ZhangH.HuH.LiY.HuZ.ZhongW.WangM.Hydroxychloroquine, a less toxic derivative"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov.620201610.1038/s41421-020-0156-032194981 127YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.LiuX.ZhaoL.DongE.SongC.ZhanS.LuR.LiH.TanW.LiuD.In vitro antiviral activity and projection"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 128SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 128SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and hydroxychloroquine"/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 128SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and hydroxychloroquine in"/>
  <result pre="analogs as a promising strategy for the treatment of emerging" exact="viral" post="diseasesPharmacol. Res. Perspect.5201710.1002/prp2.293 134FoxL.M.SaravolatzL.D.Nitazoxanide: a new thiazolide antiparasitic agentClin."/>
  <result pre="a new drug candidate for the treatment of Middle East" exact="respiratory" post="syndrome coronavirusJ. Infect. Public Health9201622723010.1016/j.jiph.2016.04.00127095301 137A.G. Canga, A.M.S. Prieto,"/>
  <result pre="new drug candidate for the treatment of Middle East respiratory" exact="syndrome" post="coronavirusJ. Infect. Public Health9201622723010.1016/j.jiph.2016.04.00127095301 137A.G. Canga, A.M.S. Prieto, M.J."/>
  <result pre="141YamamotoM.MatsuyamaS.LiX.TakedaM.KawaguchiY.InoueJ.I.MatsudaZ.Identification of nafamostat as a potent inhibitor of middle east" exact="respiratory" post="syndrome Coronavirus s protein-mediated membrane fusion using the split-protein-based"/>
  <result pre="of nafamostat as a potent inhibitor of middle east respiratory" exact="syndrome" post="Coronavirus s protein-mediated membrane fusion using the split-protein-based cell-cell"/>
  <result pre="cell-cell fusion assayAntimicrob. Agents Chemother.6020166532653910.1128/AAC.01043-1627550352 142Identification of an existing Japanese" exact="pancreatitis" post="drug, Nafamostat, which is expected to prevent the transmission"/>
  <result pre="which is expected to prevent the transmission of new coronavirus" exact="infection" post="(COVID-19)|THE INSTITUTE OF MEDICAL SCIENCE, THE UNIVERSITY OF TOKYO,"/>
  <result pre="Y. Tao, C. Xie, W. Wang, K. Shang, The Lancet" exact="Infectious" post="Diseases Dysregulation of immune response in patients with COVID-19"/>
  <result pre="Tao, C. Xie, W. Wang, K. Shang, The Lancet Infectious" exact="Diseases" post="Dysregulation of immune response in patients with COVID-19 in"/>
  <result pre="pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe" exact="pulmonary" post="syndrome patients of a new coronavirus, BioRxiv. (2020) 2020.02.12.945576."/>
  <result pre="GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary" exact="syndrome" post="patients of a new coronavirus, BioRxiv. (2020) 2020.02.12.945576. doi:10.1101/2020.02.12.945576."/>
  <result pre="BioRxiv. (2020) 2020.02.12.945576. doi:10.1101/2020.02.12.945576. 147RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseLancet3952020e30e3110.1016/S0140-6736(20)30304-432032529 148FavalliE.G.BiggioggeroM.MaioliG.CaporaliR.Baricitinib for COVID-19: a suitable treatment?Lancet Infect."/>
  <result pre="(2020) 2020.02.12.945576. doi:10.1101/2020.02.12.945576. 147RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseLancet3952020e30e3110.1016/S0140-6736(20)30304-432032529 148FavalliE.G.BiggioggeroM.MaioliG.CaporaliR.Baricitinib for COVID-19: a suitable treatment?Lancet Infect. Dis.202010.1016/s1473-3099(20)30262-0"/>
  <result pre="Liu, Can Chinese Medicine Be Used for Prevention of Corona" exact="Virus Disease" post="2019 (COVID-19)? A Review of Historical Classics, Research Evidence"/>
  <result pre="Can Chinese Medicine Be Used for Prevention of Corona Virus" exact="Disease" post="2019 (COVID-19)? A Review of Historical Classics, Research Evidence"/>
  <result pre="J. Biol. Sci.1620201708171710.7150/ijbs.4553832226288 153Diagnosis and Treatment Protocol for Novel Coronavirus" exact="Pneumonia" post="(Trial Version 6, Revised), n.d. http://en.nhc.gov.cn/2020-03/29/c_78469.htm (accessed April 15,"/>
  <result pre="more harm than goodPharmacol. Res.202010477610.1016/j.phrs.2020.104776 157LiuJ.ManheimerE.ShiY.GluudC.Chinese herbal medicine for severe" exact="acute" post="respiratory syndrome: A systematic review and meta-analysisJ. Altern. Complement."/>
  <result pre="harm than goodPharmacol. Res.202010477610.1016/j.phrs.2020.104776 157LiuJ.ManheimerE.ShiY.GluudC.Chinese herbal medicine for severe acute" exact="respiratory" post="syndrome: A systematic review and meta-analysisJ. Altern. Complement. Med.1020041041105110.1089/acm.2004.10.104115674000"/>
  <result pre="for Translational Research from the 10.13039/100000060National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID), funded by grant U19 AI142759."/>
  <result pre="Translational Research from the 10.13039/100000060National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID), funded by grant U19 AI142759."/>
 </snippets>
</snippetsTree>
